B-RAF with PLX4032: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
<scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br> | <scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene> | <scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene> | ||
<applet load='3og7' size=' | <applet load='3og7' size='600' color='white' frame='true' align='left' caption='testcaption' /> | ||
<applet load='1uwh' size=' | <applet load='1uwh' size='600' color='white' frame='true' align='right' caption='testcaption' /> | ||
Revision as of 17:30, 30 September 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanonma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
PLX 4032
Wild-Type B-RAF
V600E Mutation
PLX4032 Sulfonamide N
H-Bond Interaction Asp594 and PLX4032
DFG in
DFG out
|
|
